Pinto Alexis
Known title: Chief Legal OfficerCIK: 0001819302
Associated companies
Transaction History
| ZNTL | ▼ Sell | Open Market | 77 | $4K | 2/14/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 614 | $31K | 2/14/2022 | View on chart |
| ZNTL | ▲ Buy | Grant | 16,405 | $0 | 2/10/2022 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,800 | $137K | 10/25/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 8,098 | $626K | 10/25/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 300 | $24K | 10/25/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 19,802 | $1.5M | 10/25/2021 | View on chart |
| ZNTL | ▲ Buy | Option Exercise | 30,000 | $1.0M | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.